PERBANDINGAN STATUS ANTI-HBs (Hepatitis B surface Antibody) DAN JUMLAH LIMFOSIT PADA PESERTA PROGRAM VAKSINASI HEPATITIS B DENGAN DAN TANPA KOMORBID DIABETES MELITUS TIPE 2
DOI:
https://doi.org/10.51878/healthy.v4i4.6582Keywords:
Hepatitis B, Anti-HBs, Lymphocytes, Type 2 DM, VaccinationAbstract
Anti-HBs and lymphocyte count are used to assess the success of hepatitis B vaccination. Healthcare workers are at high risk of contracting hepatitis B, making routine vaccination essential. This study was conducted at RSUD Caruban, Madiun Regency, involving 44 participants of the hepatitis B vaccination program, both with and without type 2 diabetes mellitus comorbidity. Examinations were carried out six months post-vaccination. The study employed a comparative analytical method with a cross-sectional approach and was conducted in February 2025. The instruments used were the Eclia-Mindray CL-900i with the ELISA method and the Sysmex XN-350 with the Flow Cytometry method. In the group with type 2 diabetes mellitus, the average Anti-HBs titer was 77.53 mIU/mL, whereas in the non-diabetic group it was 882.06 mIU/mL. The average lymphocyte count was also higher in the non-diabetic group (38.91%) compared to the group with diabetes mellitus (22.52%), although both were within the normal range. There were differences in Anti-HBs status and lymphocyte counts between hepatitis B vaccination participants with and without type 2 diabetes mellitus comorbidity.
ABSTRAK
Anti-HBs dan jumlah limfosit digunakan untuk menilai keberhasilan vaksinasi hepatitis B. Tenaga kesehatan memiliki risiko tinggi tertular hepatitis B, sehingga vaksinasi rutin diperlukan. Penelitian ini dilakukan di RSUD Caruban Kabupaten Madiun, pada 44 peserta vaksinasi hepatitis B, baik dengan maupun tanpa komorbid diabetes melitus tipe 2. Pemeriksaan dilakukan enam bulan setelah vaksinasi. Penelitian ini menggunakan metode komparatif analitik dengan pendekatan cross-sectional, dilaksanakan pada bulan Februari tahun 2025. Instrumen yang digunakan adalah Eclia-Mindray CL-900i, dengan metode ELISA dan Sysmex XN-350, dengan metode Flow Cytometry. Pada kelompok dengan diabetes melitus tipe 2, rata-rata titer Anti-HBs adalah 77,53 mIU/mL, sementara kelompok tanpa diabetes melitus rata-ratanya adalah 882,06 mIU/mL. Untuk jumlah limfosit rata-ratanya lebih tinggi pada kelompok tanpa diabetes melitus yaitu sebesar 38,91 % dibandingkan kelompok dengan komorbid diabetes melitus tipe 2 sebesar 22,52%, meskipun keduanya dalam batas normal. Terdapat perbedaan status Anti-HBs dan jumlah limfosit pada peserta program vaksinasi hepatitis B dengan dan tanpa komorbid diabetes melitus tipe 2.
References
Amanatidou, E. et al. (2022). Breakthrough Infections After COVID-19 Vaccination: Insights, Perspectives and Challenges. Metabolism Open, 14, 100180. https://doi.org/10.1016/j.metop.2022.100180
Block, T. M. et al. (2021). Prospects for The Global Elimination of Hepatitis B. Annual Review of Virology, 8(1), 437. https://doi.org/10.1146/annurev-virology-091919-062728
Chu, X. et al. (2021). Genetic Factors Affecting Immune Phenotypes in Type 1 Diabetes. medRxiv. https://doi.org/10.1101/2021.12.06.21264056
Heliana, R. (2025). Hubungan Karakteristik Pasien Dengan Hasil PCR HPV DNA Di Laboratorium Medis Cito Semarang. HEALTHY Jurnal Inovasi Riset Ilmu Kesehatan, 4(3), 368. https://doi.org/10.51878/healthy.v4i3.7060
Kementerian Kesehatan Republik Indonesia. (2020). Kebijakan Vaksinasi Untuk Penyakit Menular.
Kementerian Kesehatan Republik Indonesia. (2021). Laporan Status Vaksinasi Hepatitis B Di Indonesia.
Klompas, M. (2021). Understanding Breakthrough Infections Following MRNA SARS-CoV-2 Vaccination. JAMA, 326(20), 2018. https://doi.org/10.1001/jama.2021.19063
Kumar, R. et al. (2018). Impact of Diabetes on Immunity and Vaccine Response. Journal of Diabetes Research.
Lanuti, P. et al. (2021). Picture of The Favourable Immune Profile Induced by Anti-SARS-CoV-2 Vaccination. Biomedicines, 9(8), 1035. https://doi.org/10.3390/biomedicines9081035
Marrapu, S., & Kumar, R. (2024). Chronic Hepatitis B: Prevent, Diagnose, and Treat Before The Point of No Return. World Journal of Hepatology, 16(10), 1151. https://doi.org/10.4254/wjh.v16.i10.1151
Martin, D. E. et al. (2023). Old Drug, New Tricks: The Utility of Metformin in Infection and Vaccination Responses to Influenza and SARS-CoV-2 in Older Adults. Frontiers in Aging, 4(October), 1–10. https://doi.org/10.3389/fragi.2023.1272336
Mayantie, R. D. et al. (2025). Pengaruh Penyuluhan Tentang SHK Dengan Mediavideo Terhadap Kesediaan Pemeriksaan SHK Pada BBL Di Wilayah Puskesmas Puger. HEALTHY Jurnal Inovasi Riset Ilmu Kesehatan, 4(3), 376. https://doi.org/10.51878/healthy.v4i3.7046
Meireles, L. (2015). Three Decades of Hepatitis B Control With Vaccination. World Journal of Hepatology, 7(18), 2127. https://doi.org/10.4254/wjh.v7.i18.2127
Noh, J. H. et al. (2020). Coronavirus Disease 2019 and Diabetes: The Epidemic and The Korean Diabetes Association Perspective. Diabetes & Metabolism Journal, 44(3), 372. https://doi.org/10.4093/dmj.2020.0138
Rahardiyantiningsih, N. et al. (2025). Perbedaan Prevalensi Diabetes Melitus Berdasarkan Riwayat Penggunaan Kontrasepsi Hormonal Pada Wanita Penderita Diabetes Melitus Di Uptd Puskesmas Bangsalsari. HEALTHY Jurnal Inovasi Riset Ilmu Kesehatan, 4(3), 238. https://doi.org/10.51878/healthy.v4i3.7043
Rahmani, A. et al. (2022). Long-Term Effectiveness of Hepatitis B Vaccination in The Protection of Healthcare Students in Highly Developed Countries: A Systematic Review and Meta-Analysis. Vaccines, 10(11), 1841. https://doi.org/10.3390/vaccines10111841
Rakhmina, D. et al. (2021). Immune Response to Anti-HBs Antibodies in Health Workers Following Hepatitis B Vaccination. Medical Laboratory Technology Journal, 7(2), 182–193. https://doi.org/10.31964/mltj.v7i2.418
Sei, J. J. et al. (2015). Effector and Central Memory Poly-Functional CD4+ and CD8+ T Cells Are Boosted Upon ZOSTAVAX® Vaccination. Frontiers in Immunology, 6. https://doi.org/10.3389/fimmu.2015.00553
Thimmappa, P. Y. et al. (2023). Neutrophil (Dys)Function Due to Altered Immuno-Metabolic Axis in Type 2 Diabetes: Implications in Combating Infections. Human Cell, 36(4), 1265. https://doi.org/10.1007/s13577-023-00905-7
Virgilio, E. et al. (2022). Diabetes Affects Antibody Response to SARS-CoV-2 Vaccination in Older Residents of Long-Term Care Facilities: Data From The GeroCovid Vax Study. Diabetes Care, 45(12), 2935. https://doi.org/10.2337/dc22-1255
Wang, W. et al. (2023). Characterization of Type 2 Diabetes-Related Immune Response Heterogeneity to COVID-19 Vaccines Via Single-Cell Landscape Analyses. Research Square. https://doi.org/10.21203/rs.3.rs-3677141/v1
World Health Organization. (2021). Hepatitis B. World Health Organization. Diakses pada 13 Oktober 2025, dari https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
